Starpharma Holdings First Half 2023 Earnings: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)
Starpharma Holdings (ASX:SPL) First Half 2023 Results
Key Financial Results
Revenue: AU$1.71m (down 16% from 1H 2022).
Net loss: AU$8.28m (loss narrowed by 2.0% from 1H 2022).
AU$0.02 loss per share (improved from AU$0.021 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Starpharma Holdings Earnings Insights
Looking ahead, revenue is expected to decline by 30% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Australia are expected to grow by 8.5%.
Performance of the Australian Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Starpharma Holdings you should be aware of, and 1 of them makes us a bit uncomfortable.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
